The research and development of class 1 new drugs of traditional Chinese medicine is accelerated!
It is not easy to innovate and transform, and 4 senior executives of "First Brother Medicine" have resigned within 1 year
Domestic PD-1 has fallen into a wave of price cuts, and overseas markets have become a new battlefield
Introduction of Japanese Special Purpose Foods (1)
Serious involution of PD-1?
Lactobacillus rhamnosus Probio-M9 combined with PD-1 inhibitor to improve tumor treatment effect
To regain the top 1 of global pharmaceuticals?
Sunshine Pharmaceuticals will attack 1 new drug and 3 hot varieties are just around the corner
siRNA therapy can reduce important risk factors of cardiovascular disease by 98%. Phase 1 clinical results of siRNA therapy are positive
Silence Therapeutics announced today that its investigational small interfering RNA (siRNA) therapy SLN360 has achieved
Pharmaceutical companies are in hot pursuit of innovation and R&D, with more than 20 new applications for Category 1 drug trials added within a week
Intellia and Regeneron Announce Latest Phase 1 Clinical Trial Data of NTLA-2001
On March 1, Intellia Therapeutics and Regeneron Pharmaceutical announced the latest phase 1 clinical trial data
Domestic pharmaceutical companies are attacking class 1 new drugs, and good news in this field continues
Within 1 day, the executives of China Resources Sanjiu and other two pharmaceutical companies changed
Shanghai Suspends Xinfeng Pharmaceutical's Procurement Qualification for Luotongding Sulfate Injection for 1 Year
On February 24, 2022, the Shanghai Pharmaceutical Centralized Tendering and Procurement Administration issued a notice
Phase I clinical trial of three-drug combination anti-CD40, anti-CTLA-4 and anti-PD-1 monoclonal
[Early Bird Countdown 1 Day] BioCon-Antibody's blockbuster debut agenda is open, from source to CMC
The 9th International Biopharmaceutical Conference Series-Antibody Forum was specially invited Dr.
Professor Chen Qijun's research group revealed that dihydroartemisinin regulates spleen immune cell heterogeneity through SOD3-JNK-AP-1 signaling pathway
Organic Compounds in Industrial Enterprises" (Standard No.: HJ 1230-2021), which will be implemented on April 1
Osaikang has accumulated a lot to release the first class 1 new drug benchmarking 4 billion varieties!
Osaikang has accumulated a lot, and the first class 1 new drug is benchmarked against 4 billion varieties!